If your clinic offers Spravato, or is planning to, there is one financial decision that will shape your margins more than almost anything else:
On paper, Buy and Bill looks straightforward.
You purchase the medication.
You administer it in-office.
You bill the payer.
You get reimbursed.
In real life, that is where many clinics start losing money.
Not because Spravato is unprofitable. Because the setup is wrong.
The issue is rarely one big failure. It is usually a series of smaller leaks:
If you have ever thought, “We are doing Spravato, but the margin does not feel right,” this is the article you need.
This guide breaks down how Spravato Buy and Bill works, why clinics lose money on it, and what high-performing programs do differently.
Our Spravato Billing Services are designed to simplify the business side of Spravato so clinics stop guessing and start protecting revenue.
Buy and Bill means your clinic purchases Spravato directly, administers it onsite, and then bills the patient’s insurance under the medical benefit.
That sounds simple enough. But unlike routine office visits, this model puts your clinic in a much more exposed financial position.
Because now, you are responsible for:
This is why Buy and Bill is not just a billing model. It is a financial operating model.
If you do it well, it creates strong revenue opportunity.
If you do it poorly, it creates silent losses that build over time.
In Simple Terms: Under Buy and Bill, the provider carries responsibility for purchasing, storing, administering, and billing the drug, while also taking on the reimbursement risk that comes with it.
There is a reason many mental health clinics still prefer Buy and Bill over specialty pharmacy pathways.
When managed correctly, it gives your practice more control.
That includes:
That matters because Spravato is not a one-time treatment. It is a recurring treatment model, often involving induction and maintenance scheduling over time.
When clinics have tighter control over access and supply, they usually create a smoother patient experience.
But that control only helps if your economics are set up correctly.
That is where most clinics underestimate the risk.
This is the part providers connect with immediately.
Because on the outside, the program may look busy and productive.
But under the surface, margin starts leaking in places that are easy to miss.
Let’s break down the biggest ones.
This is the first margin mistake, and one of the most expensive.
A lot of clinics accept the first pricing structure they are offered and move on. They assume the drug cost is fixed or that all distributors are roughly the same.
That assumption costs money.
If you are not actively comparing distributor terms, contract structure, and ordering economics, you are likely leaving margin on the table before the claim is even submitted.
This matters even more in Spravato because the drug cost is high enough that small differences in acquisition price can materially change profitability over time.
A few dollars per unit becomes thousands across recurring treatment volume.
That is why Our Buy & Bill Expertise goes beyond claims. Finnastra helps practices think through the purchasing side too.
Because if your cost basis is wrong, no amount of billing cleanup fully fixes the margin problem.
This is one of the most frustrating issues in Spravato.
The clinic gets the prior auth approved.
The patient starts treatment.
The claim goes out.
Then reimbursement comes back lower than expected, or the drug portion gets stuck.
Why does this happen?
Because authorization approval and billing success are not the same thing.
A prior auth may approve treatment broadly, but your claim still needs to match:
This is where clinics get caught off guard.
The treatment was clinically appropriate.
The auth existed.
But the billing structure still did not line up.
That is a cash flow problem, not just a coding problem.
This is where a lot of Spravato revenue quietly disappears.
One of the most common operational pain points we see is not a dramatic denial. It is a technical underpayment caused by incorrect drug billing structure.
That often looks like:
This is especially relevant as payer systems continue adapting to evolving drug coding logic for esketamine.
Clinics that are not reviewing these claims closely often assume the reimbursement is “close enough,” when in reality the drug side of the claim was not paid properly.
This one issue changes your Buy and Bill profitability more than most people realize.
A lot of clinics treat inventory like an operational checklist item.
It is not.
In Buy and Bill, inventory is directly tied to cash flow.
If you are purchasing Spravato, you need clean visibility into:
If those numbers do not reconcile, margin starts disappearing.
And it usually does not disappear in obvious ways.
It disappears through:
This is one of the reasons some clinics feel like they are “busy but not profitable.”
The service volume is there.
The revenue discipline is not.
This is the point where many clinics realize Buy and Bill is not only a billing issue. It is a payer strategy issue.
Not every payer reimburses the same way.
Not every contract behaves the same way.
Not every payment pattern supports healthy margins.
That means if your clinic is treating all payers as equally viable for Spravato, you may be exposing yourself to unnecessary reimbursement drag.
A profitable Spravato program usually requires active review of:
CMS continues to publish quarterly ASP payment files because reimbursement for provider-administered drugs is deeply tied to changing payment benchmarks and coding/payment logic. Even outside Medicare, those benchmarks influence how clinics think about reimbursement discipline and margin sensitivity.
That is why a healthy Buy and Bill program is not built only on claim submission. It is built on reimbursement analysis.
As a leading Spravato Billing Services Company, Finnastra ensures clinics are not simply billing more, but billing in a way that protects actual profitability.
This is another major reason clinics lose money on Spravato.
The claim gets submitted.
Then everyone moves on.
A few weeks later, maybe someone checks payment.
A few weeks after that, maybe someone notices an underpayment.
By then, the urgency is gone and the AR is already aging.
That is how money gets trapped.
And with Buy and Bill, slow collections hurt more because the clinic already paid for the medication upfront.
That means every delayed claim creates real working capital pressure.
Our 2025 claims data shows denial pressure is still high across healthcare, with many organizations reporting 10% or more of claims denied and 68% saying clean claim submission is more difficult than a year earlier.
In Spravato, that risk becomes even more expensive because you are not only chasing professional reimbursement. You are chasing drug reimbursement too.
That is why clean claims are not enough.
You need fast follow-through.
The clinics that make Buy and Bill work well do not rely on luck. They rely on clean systems, strong controls, and the right billing partner.
At Finnastra, this is what we do to help practices protect revenue and improve margins:
When you work with a dedicated Spravato Billing Company like Finnastra, this is the kind of financial visibility and control you should expect behind the scenes.
These are the day-to-day questions providers actually care about:
Those are not niche questions.
Those are revenue questions.
And they deserve a structured answer, not billing guesswork.
At Finnastra, we do not treat Buy and Bill as “submit the claim and see what happens.”
We treat it like what it is: a margin-sensitive specialty treatment model.
As a leading Spravato Billing Services Company, Finnastra ensures:
Our Spravato Billing Services are designed to simplify the reimbursement side and the business side of Spravato.
When you work with a dedicated Spravato Billing Company like Finnastra, your clinic gets support that is built around profitability, not only process.
That is the difference.
Buy and Bill will absolutely work for Spravato.
In many cases, it is the right model.
But it only works well when the numbers are being protected from both ends:
That is where clinics either create a healthy revenue stream or slowly lose margin without realizing why.
If your practice is offering Spravato, planning to launch, or trying to figure out why the program is not as profitable as it should be, Finnastra can help.
We help clinics tighten the operational side, clean up the billing side, and protect the financial side.
